Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies

Journal of Clinical Oncology

Volumn 20, Issue 17, 2002, Pages 3683-3690

  Goh, Boon Cher ^a   Lee, Soo Chin ^a   Wang, Ling Zhi ^a   Fan, Lu ^a   Guo, Jia Yi ^a   Lamba, Jatinder ^a   Schuetz, Erin ^a   Lim, Robert ^a   Lim, Hong Liang ^a   Ong, Ai Bee ^a   Lee, How Sung ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; CYTOCHROME P450 3A5; DOCETAXEL; GLYCOPROTEIN P; MIDAZOLAM; OROSOMUCOID; SERUM ALBUMIN;

5' UNTRANSLATED REGION; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASIAN; CLINICAL ARTICLE; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; GENETIC POLYMORPHISM; GENOTYPE PHENOTYPE CORRELATION; HOMOZYGOSITY; HUMAN; MALE; NEUTROPHIL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BLOOD LEVEL;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; ETHNIC GROUPS; FEMALE; GENES, MDR; GENOTYPE; HUMANS; LINEAR MODELS; MALE; METABOLIC CLEARANCE RATE; MIDAZOLAM; MIDDLE AGED; MULTIVARIATE ANALYSIS; OXIDOREDUCTASES, N-DEMETHYLATING; PACLITAXEL; PHENOTYPE; POLYMORPHISM, GENETIC; TAXOIDS;

EID: 0036731724     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.01.025     Document Type: Article

References (43)

1. Ethnic differences in drug disposition and response
2. Ethnic differences in drug metabolism
3. Populations and genetic polymorphism
4. Geographic/interracial differences in polymorphic drug oxidation
5. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasians and Chinese subjects
6. Pronounced differences between native Chinese and Swedish populations of debrisoquin and S-mephenytoin
7. Ethnic distribution of slow acetylator mutations in the polymorphic N+ acetyltransferase (NAT2) gene
8. Pharmacogenomics
9. Pharmacogenomics: Translating functional genomics into rational therapeutics
10. Racial differences in the response to drugs: Pointers to genetic differences
11. Phase II trial of docetaxel in Asian patients with inoperable stage III non-small cell lung cancer
12. Hepatic biotransformation of docetaxel (taxotere) in vitro: Involvement of the CYP 3A subfamily in humans
13. Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans
14. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and Caucasians
15. Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP 3A4
16. Association of CYP3A4 genotype with treatment-related leukemia
17. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP 3A4
18. Sequence diversity in CYP 3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
19. Altered pharmacokinetics of vinblastine in Mdrla P-glycoprotein-deficient mice
20. Purification of P-glycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability
21. Expression of a full-length cDNA for the human "MDRI" gene confers resistance to colchicines, doxorubicin, and vinblastine
22. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissue
23. MDR 1 limits CYP3A metabolism in vivo
24. Functional polymorphisms of the human multi-drug resistance gene: Multiple sequence variations and correlation of one allele with p-glycoprotein expression and activity in vivo
25. Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed phase high performance liquid chromatography
26. Use of midazolam as a human cytochrome P450 probe: 1. In vitro-in vivo correlations in liver transplant patients
27. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects
28. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer
29. Clinical pharmacokinetics of docetaxel
30. Population pharmacokinetics of docetaxel in Japanese patients
31. Differences in the urinary excretion of 6-beta-hydroxycortisol/cortisol between Asian and Caucasian women
32. The effect of an individual's cytochrome CYP 3A4 activity on docetaxel clearance
33. Correlation between docetaxel clearance and estimated cytochrome p 450 activity by urinary metabolite of exogenous cortisol
34. Absence of correlations among three putative in vivo probes of human cytochrome p 4503A activity in young healthy men
35. In vivo comparison of putative probes of CYP3A4/5 activity: Erythromycin, dextromethorphan, and verapamil
36. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P 4503A
37. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450
38. The erythromycin breath test predicts the clearance of midazolam
39. The erythromycin breath test for the prediction of drug clearance
40. Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells
41. A population model for docetaxel (Taxotere): Model building and validation
42. Novel mutations of CYP 3A4 in Chinese
43. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine